Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation
Translation Control Discovery Platform
A new strategy against hard and undruggable targets
Specifically decrease or increase the production of target proteins
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
• Analysis Assessment
• Bio Data Analysis
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact firstname.lastname@example.org.
17 Scientific Collaborations
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
Nucleic Acid Res. (2017); 45 :926-937
News & Events
BioCentury 26th Annual Future Leaders in the Biotech Industry Conference
When: Apr. 12th, 2019
Where: New York, USA
Anima Biotech has been invited to present and participate on a panel during the BioCentury 26th Annual Future Leaders in the Biotech Industry Conference.
The Future Leaders Class of 2019 will showcase the next wave of investment opportunities in redefining disease, expanding the world of druggable targets, advancing next-generation modalities and applying AI to drug development.
13th Annual BIO-Europe Spring International Partnering Conference
When: Mar. 25th, 2019 - Mar. 27th, 2019
Where: Vienna, Austria
Anima Biotech has been invited to present about its business, technology and partnering strategies during the 13th Annual BIO-Europe Spring International Partnering Conference.
The Annual BIO-Europe Spring Conference is Europe’s largest springtime biotech partnering event. The conference attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and mid-size pharmaceutical companies, investors and other industry experts.
2019 BIO Asia
When: Mar. 5th, 2019 - Mar. 6th, 2019
Where: Tokyo, Japan
Anima Biotech has been invited to present about its business and partnering strategies at the 2019 BIO Asia International Conference.
The Annual BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements.
Over the years, as Anima was still developing its technology platform, I attended many conferences in which I was selling our vision to pharma. I always received these responses; "this is so novel," "this platform has huge potential," but also heard "this is very early," "what results do you...
January 31st, 2019